Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847523 | 1.00 | ABL1 (0.47) | ABL1KMT2ASMN1; SMN2MEN1DEGS1 | |
| SCHEMBL2842200 | 0.84 | ABL1 (0.49) | ABL1KMT2ASMN1; SMN2MEN1DEGS1 | |
| SCHEMBL2842199 | 0.84 | ABL1 (0.49) | ABL1KMT2ASMN1; SMN2MEN1DEGS1 | |
| SCHEMBL2849284 | 0.79 | ABL1 (0.46) | ABL1KMT2ASMN1; SMN2MEN1DEGS1 | |
| SCHEMBL2849286 | 0.79 | ABL1 (0.46) | ABL1KMT2ASMN1; SMN2MEN1DEGS1 | |
| SCHEMBL13090478 | 0.79 | ABL1 (0.64) | ABL1KMT2ASMN1; SMN2MEN1DEGS1 | |
| SCHEMBL2853507 | 0.77 | ELOVL6 (0.47) | ABL1KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2853508 | 0.77 | ELOVL6 (0.47) | ABL1KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2849781 | 0.75 | ABL1 (0.48) | ABL1KMT2ASMN1; SMN2MEN1DEGS1 | |
| SCHEMBL2849782 | 0.75 | ABL1 (0.48) | ABL1KMT2ASMN1; SMN2MEN1DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2236494-B1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD KK (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-2236494-A1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | CHRM2, CHRM3, CHRM1 | ABL1 3478/4885KMT2A 1869/4885SMN1; SMN2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.